Neurokinin-1 Receptor Antagonists
"Neurokinin-1 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.
| Descriptor ID |
D064729
|
| MeSH Number(s) |
D27.505.519.625.487 D27.505.696.577.487
|
| Concept/Terms |
Neurokinin-1 Receptor Antagonists- Neurokinin-1 Receptor Antagonists
- Antagonists, Neurokinin-1 Receptor
- Neurokinin 1 Receptor Antagonists
- Receptor Antagonists, Neurokinin-1
- Neuroleukin-1 Receptor Blockers
- Blockers, Neuroleukin-1 Receptor
- Neuroleukin 1 Receptor Blockers
- Receptor Blockers, Neuroleukin-1
- Substance P Receptor Antagonists
- Tachykinin Receptor 1 Antagonists
- Tachykinin Receptor 1 Blockers
- Neurokinin-1 Receptor Blockers
- Blockers, Neurokinin-1 Receptor
- Neurokinin 1 Receptor Blockers
- Receptor Blockers, Neurokinin-1
- Substance P Receptor Blockers
|
Below are MeSH descriptors whose meaning is more general than "Neurokinin-1 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Neurokinin-1 Receptor Antagonists".
This graph shows the total number of publications written about "Neurokinin-1 Receptor Antagonists" by people in this website by year, and whether "Neurokinin-1 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurokinin-1 Receptor Antagonists" by people in Profiles.
-
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
-
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
-
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol. 2019 Jan; 15(3):241-255.
-
Pruritus in Cutaneous T-Cell Lymphoma and Its Management. Dermatol Clin. 2018 Jul; 36(3):245-258.
-
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
-
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
-
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer. 2017 01; 25(1):85-92.
-
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Drugs Today (Barc). 2016 Aug; 52(8):431-438.
-
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
-
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.